2023 - 1
|
| Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes |
| Bottcher Michael Friedrich , Dungen Hans-Dirk , Corcea Vasile Ion, Donath Frank , Fuhr Rainard , Gal Pim , Mikus Gerd , Trenk Dietmar , Coenen Martin , Pires Philippe Vieira , Maschke Claudia , Aliprantis Antonios Othon , Besche Nina , Becker Corina |
1 Clinical Pharmacology, Wuppertal,
2 Charité - University Medicine Berlin,
3 Timofei Moșneaga Republican Clinical Hospital,
4 SocraTec R and D GmbH, Erfurt,
5 Early Phase Clinical Unit, Berlin,
6 Centre for Human Drug Research, Leiden,
7 Leiden University Medical Center,
8 University Hospital Heidelberg,
9 University Medical Center Freiburg,
10 University Hospital Bonn,
11 Research and Development, Bayer AG, Wuppertal,
12 Study Management, Bayer AG, Wuppertal,
13 Translational Medicine, Merck and Co., Inc., New Jersey ,
14 Chrestos Concept GmbH and Co. KG, Essen |
| American Journal of Cardiovascular Drugs |
| Nr. / 2023 / ISSN 1175-3277 / ISSNe 1179-187X |
| Disponibil online 28 February, 2023 |
-----------------------------------------------------------------------------------------------------------------------------------
